istock-625888460mraoraor
mraoraor / iStockphoto.com
1 October 2018Americas

Teva sues Eli Lilly again after FDA approves migraine drug

Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly gained Food and Drug Administration (FDA) approval to market Emgality (galcanezumab-gnlm).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.

More on this story

Americas
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.

More on this story

Americas
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.